key articles
External validation of the Mayo Clinic Cancer Specific Survival Score in a Japanese series of clear cell renal cell carcinoma
Monday, 15 September 2008 - Fujii et al. (2008) validated the Mayo Clinic SSIGN (stage, size, grade and necrosis) score in an independent Japanese sample of patients.
Between 1985 and 2006, 406 consecutive Japanese patients...
Authors: Fujii et al.
Pathological tumour diameter predicts risk of conventional subtype in small renal cortical tumours
Wednesday, 10 September 2008 - Laudano et al. (2008) examined whether pathological tumour diameter assists in predicting conventional vs other histological subtypes in renal cortical tumours (RCTs) of < /=4 cm diameter.
In all,...
Authors: Laudano et al.
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
Wednesday, 10 September 2008 - Remak et al. (2008) assessed the cost effectiveness of sunitinib malate as a first-line treatment in metastatic renal cell carcinoma (mRCC) compared with interferon-alfa (IFN-alpha) and...
Authors: Remak et al.
Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma
Wednesday, 10 September 2008 - Zini et al. (2008) examined the cancer-specific survival of patients treated with nephrectomy and compared it to that of patients managed without surgery.
Of 43 143 patients with renal cell...
Authors: Zini et al.
Oncological comparison of laparoscopic nephroureterectomy with open nephroureterectomy
Monday, 8 September 2008 - Waldert et al. (2008) compared the overall, tumour-specific, recurrence-free, and progression- free survival of patients with upper urinary tract transitional cell carcinoma (UUT-TCC) treated with...
Authors: Waldert et al.
Two renal veins are not a contraindication for retroperitoneoscopic right-side donor nephrectomy
Thursday, 4 September 2008 - Modi and Rizvi (2008) evaluated the results of right-donor nephrectomy with kidneys having two or more renal veins.
Between September 2004 and August 2007, 50 right-side donor nephrectomies were...
Authors: Modi and Rizvi
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma
Thursday, 4 September 2008 - Marur et al. (2008) evaluated the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial.
Eligibility included metastatic renal cancer with a maximum of 2 prior...
Authors: Marur et al.
Induction of apoptosis in renal cell carcinoma cells by vitamin E succinate in caspase-independent manner
Thursday, 4 September 2008 - Renal cell carcinoma (RCC) is one of the most drug-resistant malignancies, and an effective therapy is lacking for metastatic RCC. Vitamin E (VE) has been intensively studied as a chemopreventive...
Authors: Wu et al.
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy
Wednesday, 3 September 2008 - Since the introduction of tyrosine kinase inhibitors (TKI), treatment of metastatic renal cell carcinoma (RCC) has undergone dramatic changes. However, the use of TKI therapy in adjunctive settings...
Authors: Amin et al.
Sequential use of tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma
Monday, 1 September 2008 - Few data are available now about the sequential use of the tyrosine kinase inhibitors (TKI) sorafenib and sunitinib in metastatic renal cell carcinoma (mRCC). Eichelberg et al. (2008)investigated the...
Authors: Eichelberg et al.
